Document is current
Any future updates will be listed below
-
Authors
Knutson, Todd P. https://orcid.org/0000-0001-8431-9964
Luo, Bin https://orcid.org/0000-0002-3983-5676
Kobilka, Anna
Lyman, Jacqueline
Guo, Siyuan
Munro, Sarah A.
Li, Yingming
Heer, Rakesh
Gaughan, Luke
Morris, Michael J. https://orcid.org/0000-0002-9454-0096
Beltran, Himisha https://orcid.org/0000-0003-3259-2226
Ryan, Charles J.
Antonarakis, Emmanuel S. https://orcid.org/0000-0003-3531-3851
Armstrong, Andrew J. https://orcid.org/0000-0001-7012-1754
Halabi, Susan https://orcid.org/0000-0003-4135-2777
Dehm, Scott M. https://orcid.org/0000-0002-7827-5579
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA256157, R01CA174777, R01CA270539)
Prostate Cancer Foundation (18CHAL11)
- License Information
-
More Information
Article History
Received: 9 January 2024
Accepted: 21 November 2024
First Online: 11 December 2024
Competing interests
: MJM has served as a consultant to Lantheus, AstraZeneca, Daiichi, Convergent Therapeutics, Pfizer, ITM Isotopes, Clarity Pharmaceuticals, Blue Earth Diagnostics, POINT Biopharma, Telix, Z-Alpha, AMBRX, Flare Therapeutics, Fusion Pharmaceuticals, Curium, Transtherabio, Celgene, Arvinas, and Exelixis. His institution receives royalty payments from Telix, and research funding from Novartis, Fusion, and Astellas. HB has served as consultant/advisory board member for Janssen, Astellas, Merck, Pfizer, Foundation Medicine, Blue Earth Diagnostics, Amgen, Bayer, Oncorus, LOXO, Daicchi Sankyo, Sanofi, Curie Therapeutics, Astra Zeneca, Novartis, and has received research funding (institution) from Janssen, AbbVie/Stemcentrx, Eli Lilly, Astellas, Millennium, Bristol Myers Squibb, Circle Pharma, Daicchi Sankyo, Novartis. CJR has served as a consultant to Oric, Pfizer, Bayer, and Sanofi. ESA is a paid consultant/advisor to Janssen, Astellas, Sanofi, Dendreon, Pfizer, Amgen, Eli Lilly, Bayer, AstraZeneca, Bristol Myers Squibb, ESSA, Clovis, Merck, Curium, Blue Earth Diagnostics, Foundation Medicine, Exact Sciences and Invitae; has received research funding to his institution from Janssen, Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, Tokai, Bristol Myers Squibb, Constellation, Bayer, AstraZeneca, Clovis and Merck; and is the coinventor of a patented AR-V7 biomarker technology that has been licensed to Qiagen. AJA reports research support (to Duke) from the NIH/NCI, PCF/Movember, DOD, Astellas, Pfizer, Bayer, Janssen, Dendreon, BMS, AstraZeneca, Merck, Forma, Celgene, Amgen, Novartis. AJA reports consulting or advising relationships with Astellas, Pfizer, Bayer, Janssen, BMS, AstraZeneca, Merck, Forma, Celgene, Myovant, Exelixis, GoodRx, Novartis, Medscape, MJH, Z Alpha, Telix. SH is a member of the Data Monitoring Committees (DMCs) for Aveo, Beigene, BMS, CG Oncology, J&J, Sanofi and was funded by grant awarded to Duke University by ASCO and Astellas. SMD has served as a paid consultant/advisor to Janssen, Bristol Myers Squibb, and Oncternal Therapeutics, and has served as principal investigator on grants awarded to the University of Minnesota by Janssen and Pfizer/Astellas. The remaining authors declare no competing interests.
